Research programme: peptide hybrids - Amylin PharmaceuticalsAlternative Names: AC 164209; Amylinomimetic/GRA peptide hybrid; GLP-1 receptor agonist/amylin analogue hybrid; GLP-1 receptor agonist/amylin mimetic hybrid; GLP-1 receptor agonist/amylinomimetic hybrid; GRA/amylinomimetic peptide hybrid; INTO
Latest Information Update: 12 Nov 2013
At a glance
- Originator Amylin Pharmaceuticals
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Islet amyloid polypeptide stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity